dosage when switching from semaglutide to tirzepatide Early Dose Escalation of after in Type 2 Diabetes Mellitus when I have people that

doi: 10.1016/j.isci.2024.110670 158 ShikumaCMChewGMKohornLSouzaSAChowDSahBandarINet al

We look at when the QC samples were run, whether the control samples passed, etc

Why Blood Sugar May Not Be Very High In classic DKA: Insulin deficiency severe hyperglycemia In euglycemic DKA: Some insulin is still being administered Blood glucose may appear only mildly elevated But insulin is insufficient to prevent ketogenesis This can delay recognition because: Patients and clinicians may not suspect DKA with glucose under 250 mg/dL Symptoms may initially resemble dehydration or GI illness Additional Contributing Factors GLP-1 use in Type 1 diabetes may also increase DKA risk due to: Vomiting dehydration stress hormones ketone rise Intentional insulin reduction due to fear of hypoglycemia Reduced basal insulin during weight loss Increased glycemic variability from delayed gastric emptying Hypoglycemia and the Insulin Reduction Trap Another issue is the cycle that can develop: Appetite decreases Insulin dose is reduced Hypoglycemia occurs intermittently Insulin is reduced further Ketone production increases Over time, this can push the patient into metabolic instability

Wegovy is available as both an injection and an oral tablet, though the ingredients and function remain the same: a semaglutide-based single-agent agonist

The best medication is the one you can access, afford, tolerate, and stay on consistently